BIOMAT Database Logo BIOMAT Database Logo

Plasma and cerebrospinal pharmacokinetics and pharmacodynamics in subjects taking lopinavir/ritonavir. 2006

Troy M Martin, and Gene D Morse, and Jaclynn Kurpewski, and Robin Difrancesco, and Angela M Caliendo, and Timothy P Flanigan, and Karen T Tashima

UI MeSH Term Description Entries
D008297 Male Males
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D061466 Lopinavir An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A. A-157378.0,ABT 378,ABT-378,N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide,A 157378.0,A157378.0,ABT378
D019438 Ritonavir An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A. ABT 538,ABT-538,Norvir,ABT538

Related Publications

Troy M Martin, and Gene D Morse, and Jaclynn Kurpewski, and Robin Difrancesco, and Angela M Caliendo, and Timothy P Flanigan, and Karen T Tashima
Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir.
September 2003, AIDS patient care and STDs,
Troy M Martin, and Gene D Morse, and Jaclynn Kurpewski, and Robin Difrancesco, and Angela M Caliendo, and Timothy P Flanigan, and Karen T Tashima
Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.
October 2002, AIDS (London, England),
Troy M Martin, and Gene D Morse, and Jaclynn Kurpewski, and Robin Difrancesco, and Angela M Caliendo, and Timothy P Flanigan, and Karen T Tashima
Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects.
August 2006, Clinical pharmacology and therapeutics,
Troy M Martin, and Gene D Morse, and Jaclynn Kurpewski, and Robin Difrancesco, and Angela M Caliendo, and Timothy P Flanigan, and Karen T Tashima
Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.
January 2007, Clinical pharmacology and therapeutics,
Troy M Martin, and Gene D Morse, and Jaclynn Kurpewski, and Robin Difrancesco, and Angela M Caliendo, and Timothy P Flanigan, and Karen T Tashima
Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
January 2004, Scandinavian journal of infectious diseases,
Troy M Martin, and Gene D Morse, and Jaclynn Kurpewski, and Robin Difrancesco, and Angela M Caliendo, and Timothy P Flanigan, and Karen T Tashima
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
January 2007, Antiviral therapy,
Troy M Martin, and Gene D Morse, and Jaclynn Kurpewski, and Robin Difrancesco, and Angela M Caliendo, and Timothy P Flanigan, and Karen T Tashima
Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.
April 2004, Journal of acquired immune deficiency syndromes (1999),
Troy M Martin, and Gene D Morse, and Jaclynn Kurpewski, and Robin Difrancesco, and Angela M Caliendo, and Timothy P Flanigan, and Karen T Tashima
Lopinavir/ritonavir population pharmacokinetics in neonates and infants.
June 2011, British journal of clinical pharmacology,
Troy M Martin, and Gene D Morse, and Jaclynn Kurpewski, and Robin Difrancesco, and Angela M Caliendo, and Timothy P Flanigan, and Karen T Tashima
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.
August 2004, The Journal of antimicrobial chemotherapy,
Troy M Martin, and Gene D Morse, and Jaclynn Kurpewski, and Robin Difrancesco, and Angela M Caliendo, and Timothy P Flanigan, and Karen T Tashima
The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.
September 2006, British journal of clinical pharmacology,
Copied contents to your clipboard!